Association of ideal body weight–normalized post-transplantation cyclophosphamide dose with chronic GVHD in patients with overweight/obesity

Figures

• 

  Fig. 1. Cumulative incidence of chronic GVHD according to IBW-normalized total PTCy dose in overweight and obese recipients. The cumulative incidence of chronic graft-versus-host disease (cGVHD) was compared between overweight/obese recipients who received <100 mg/kg ideal body weight (IBW) and ≥100 mg/kg IBW total post-transplantation cyclophosphamide (PTCy). The 1-year cumulative incidence was 68.5% (95% CI, 21.3–91.2) in the <100 mg/kg IBW group, and 10.0% (95% CI, 0.6–35.8) in the ≥100 mg/kg IBW group (p = 0.03). Cumulative incidence curves were estimated using the cumulative incidence function, treating relapse, subsequent transplantation, and death as competing events. Group comparisons were performed using Gray’s test. Tick marks indicate censoring, and numbers at risk are presented below the plot.